SANOFI PASTEUR
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Subsidiary
- Established
- 1990-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.sanofipasteur.com
Safety and Immunogenicity of an Intramuscular Pandemic Influenza Vaccine in Adults and the Elderly
Phase 2
Completed
- Conditions
- InfluenzaOrthomyxoviridae Infections
- Interventions
- Biological: A/H5N1 inactivated, split-virion influenza virus
- First Posted Date
- 2006-12-22
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 600
- Registration Number
- NCT00415129
Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants
Phase 3
Completed
- Conditions
- DiphtheriaPoliomyelitisPertussisTetanusHepatitis B
- Interventions
- Biological: DTaP-IPV-HB-PRP~T vaccineBiological: DTaP-HBV-IPV vaccine
- First Posted Date
- 2006-11-29
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 1189
- Registration Number
- NCT00404651
Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants
Phase 3
Completed
- Conditions
- Hepatitis BPolioDiphtheriaPertussisHaemophilus Influenzae Type b
- Interventions
- Biological: DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccinesBiological: DTaP-HB-IPV and Pneumococcal polysaccharide vaccines
- First Posted Date
- 2006-11-20
- Last Posted Date
- 2014-04-01
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 412
- Registration Number
- NCT00401531
Safety of REPEVAX® Given One Month After REVAXIS®
Phase 3
Completed
- Conditions
- Healthy Adult
- Interventions
- Biological: REPEVAX® after PlaceboBiological: REPEVAX® after REVAXIS®
- First Posted Date
- 2006-11-16
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 500
- Registration Number
- NCT00400309
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase 3
Completed
- Conditions
- Myxovirus InfectionOrthomyxoviridae InfectionInfluenza
- Interventions
- Biological: High-Dose Inactivated, Split-Virion Influenza VaccineBiological: Inactivated, Split-Virion Influenza Vaccine
- First Posted Date
- 2006-10-23
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 3851
- Registration Number
- NCT00391053
Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.
Phase 4
Completed
- Conditions
- Influenza
- Interventions
- Biological: Influenza Virus Vaccine, Fluzone®
- First Posted Date
- 2006-10-23
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 173
- Registration Number
- NCT00390884
Trial to Collect Safety Data and Sera for Immunogenicity Testing
Phase 4
Completed
- Conditions
- Influenza
- Interventions
- Biological: Influenza Virus Vaccine (Fluzone®)
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 31
- Registration Number
- NCT00389857
Phase IV Trial to Determine the Safety and Immunogenicity of the WHO Formulation of the 2006-2007 Fluzone® Vaccine
Phase 4
Completed
- Conditions
- Influenza
- Interventions
- Biological: Influenza Virus Vaccine (2006-2007 Fluzone® vaccine)
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 116
- Registration Number
- NCT00389532
Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)
Phase 1
Withdrawn
- Conditions
- SmallpoxAtopic Dermatitis
- Interventions
- Biological: MVA (smallpox vaccine)
- First Posted Date
- 2006-10-18
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Registration Number
- NCT00389103
- Locations
- 🇺🇸
Academic Dermatology Associates, Albuquerque, New Mexico, United States
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
🇺🇸DermResearch, Inc., Austin, Texas, United States
A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers
Phase 3
Completed
- Conditions
- Meningococcal MeningitisMeaslesMumpsRubellaVaricella
- Interventions
- Biological: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate VaccineBiological: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
- First Posted Date
- 2006-10-06
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 1128
- Registration Number
- NCT00384397
© Copyright 2025. All Rights Reserved by MedPath